AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
REDWOOD CITY, Calif., May 6, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at The Tenth Annual JMP Securities Research Conference at the San Francisco Ritz Carlton. The presentation is scheduled for Monday, May 9, 2011 at 12:30p.m. PT.
The presentation will be webcast live and can be accessed through http://wsw.com/webcast/jmp13/acrx/. For those who are not available to listen to the live broadcast, the presentation will be archived and available through http://www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab(TM) PCA System, which has completed Phase 2 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA) which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.
SOURCE AcelRx Pharmaceuticals, Inc.